BASF increases prices for pharmaceutical excipients and active ingredients
This price increase affects the entire excipients portfolio including the Kollidon®, Kollicoat®, Cremophor®, and Lutrol® brands. The affected active pharmaceutical ingredient (API) portfolio contains products like Ibuprofen, Caffeine, and Ephedrine.
Due to the continued rise in costs for raw materials, energy and labor this price increase has become necessary. All existing contractual obligations will be honored.
Most read news
Other news from the department price development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.